President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come
Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.
You may also be interested in...
Medicare pricing decisions will become ‘highly politicized,’ Scott Gottlieb predicts. The former FDA commissioner and CMS official also believes the program should rely on outside health technology assessment groups, and he offers his opinions on how negotiation will (or won’t) change patent litigation.
Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference
Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.